Health Information
Health Education
Health EducationIdarubicin 認識化療藥品Zavedos
2024/1/22Idarubicin is classified as an anthracyline anticancer antibiotic. This drug inhibits DNA synthesis by producing DNA cross-links which halt cell replication and eventually causing cell death.
Aldesleukin 認識化療藥品Aldesleukin
2024/1/22Aldesleukin is a synthetic interleukin-2 that stimulates the immune system by encouraging the growth of certain white blood cells called T lymphocytes and natural killer cells in the body. This helps the body fight cancers.
Capecitabine 認識化療藥品Capecitabine
2024/1/22Capcitabine is classified as an anticancer antimetabolites. This medicine inhibits thymidylate synthase that is essential for the formation of DNA and RNA. This stops the growth of cancer cells, causing the cancer cells to die.
Granulocyte colony-stimulating factor (G-CSF) 認識化療藥品G-CSF
2024/1/22G-CSF is a growth factor that stimulates the bone marrow to produce more blood cells.
UFT 認識化療藥品UFUR
2024/1/22UFT is classified as anticancer antimetabolites. UFT is made up of two drugs that are combined together: tegafur and uracil. This medicine inhibits thymidylate synthase that is essential for the formation of DNA and RNA. This stops the growth of cancer cells, causing the cancer cells to die.
Interferon alfa-2a 認識化療藥品Referon-A
2024/1/22Roferon-A® is a synthetic interferon alfa-2a that stimulates T cells and other immune system cells to fight certain types of cancer.
Liposomal doxorubicin 認識化療藥品Lipo-Dox
2024/1/22Lipo-Dox® is doxorubicin covered in tiny spheres called liposomes. These spheres keep the doxorubicin in the bloodstream longer and has more time to reach the tumor tissue, thus significantly lowering the side effects.
Oxaliplatin 認識化療藥品Oxaliplatin
2024/1/22Oxaliplatin, a platinum compound, is an alkylating agent that exerts its anticancer activity by reacting with DNA and interfering with DNA replication and cell division. This stops the growth and spread of cancer cell in the body.
Rituximab 認識標靶藥品Rituximab
2024/1/22Rituximab is a monoclonal antibody that targets to a protein called CD20 on the surface of white blood cells known as B lymphocytes. When rituximab sticks to the surface of these cells, the abnormal growth of the B lymphocytes is stopped and triggers cell death.
Bevacizumab 認識標靶藥品Bevacizumab
2024/1/22Bevacizumab is a monoclonal antibody that targets to the protein called endothelial growth factor (VEGF), thereby inhibiting the binding of VEGF to its receptors. As a result, bevacizumab prevents the growth of the new blood vessels, thereby reducing oxygen and nutrients to the tumor. This can interfere with cancer cell growth and expansion.